Avestar Capital’s DexCom DXCM Stock Holding History

Avestar Capital’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,000	Closed	-$137K	–	497
2025 Q1	$137K	Hold	2,000	–	–	0.01%	471
2024 Q4	$156K	Hold	2,000	–	–	0.01%	492
2024 Q3	$134K	Buy	+2,000	New	+$164K	0.01%	449

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Avestar Capital's DXCM Position: Q3 2025 in Review

Avestar Capital sold out of DexCom (DXCM) in Q3 2025, closing a stake of 3,951 shares — an estimated $345K sold.

Avestar Capital first reported a position in DXCM in Q1 2019 and held it in 12 quarters. The position peaked at $454K in Q4 2024. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Avestar Capital reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Avestar Capital sold 3,951 DexCom shares in Q3 2025, an estimated $345K.
Avestar Capital first reported a position in DexCom in Q1 2019 and held it in 12 quarters.
Avestar Capital's DexCom position peaked at $454K in Q4 2024.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Avestar Capital's 13F filing for Q3 2025, filed 7 Nov 2025.